Renal Artery Thromboembolism and Immunosuppressive Therapy

F. Florian Kronenberg
K. Karl Lhotta
A. Alfred Königsrainer
P. Paul König

Institute of Medical Biology and Human Genetics, Innsbruck, and Departments of Clinical Nephrology and Transplant Surgery, University Hospital, Innsbruck, Austria

Dr. Florian Kronenberg, Institute of Medical Biology and Human Genetics, Schöpfstrasse 41, A-6020 Innsbruck (Austria)

Dear Sir,

Lo et al. [1] reported a case of recurrent allograft kidney infarction secondary to embolization from a thrombus of the hypogastric artery as extremely rare complication. We observed in 1 out of 244 renal transplant recipients a thromboembolic complication of the allograft renal artery 22 months after transplantation. The patient was a 42-year-old man with chronic pyelonephritis as cause for the renal insufficiency. Immunosuppressive therapy consisted of ciclosporin A (CsA) and prednisone (P) since transplantation.

Recently we investigated the occurrence of thromboembolic complications during the 1st year following renal transplantation in 244 patients treated either with a combination of CsA and P (CsA+P) (n = 118) or with a triple-drug therapy (CsA+P+azathioprine) (n = 126) [2]. A total of 41 thromboembolic complications occurred in 33 patients, most being thromboses of the leg veins, myocardial infarctions, or cerebrovascular accidents. The patients treated with the CsA+P therapy showed a significantly higher incidence of thromboembolic complications as compared with patients treated with the triple-drug therapy (19.5 vs. 7.9%; p < 0.01). During the preceding months, patients with thromboembolic complications have had significantly higher CsA whole-blood levels than patients without complications (CsA+P 117 ± 21 vs. 80 ± 13 ng/ml, p = 0.005; triple-drug treatment 102 ± 28 vs. 59 ± 11 ng/ml, p = 0.001 – monoclonal radioimmunoassay). The patient reported above had mean CsA blood levels of 475 ng/ml (polyclonal radioimmunoassay) during the preceding 6 months which was much higher as in patients without complications (287 ± 51 ng/ml; polyclonal radioimmunoassay).

CsA causes a vasoconstriction by an enhanced release of thromboxane A2 [3] and a decreased production of prostacyclin [4]. Furthermore, CsA is a direct cause of pronounced vascular endothelial damage [5], endothelin (one of the most potent vasoconstrictors) release [6], and increased thrombo-cyte aggregation. Together these conditions are highly thrombogenic. Lo et al. [1] reported CsA trough level of 176 ng/ml in their case report which is also clearly higher than in our patients with thromboembolic complications.

With the introduction of triple-drug therapy and the ensuing dose reduction for the individual drugs, a decline in thromboembolic complications was anticipated which was demonstrated in our study [2]. This favours the use of triple-drug instead of CsA+P therapy for the prevention or reduction of thromboembolic complications.
References